<DOC>
	<DOCNO>NCT02114385</DOCNO>
	<brief_summary>Primary objective To demonstrate administration 9vHPV vaccine induces non-inferior Geometric Mean Titres ( GMTs ) serum anti-HPV 6 , 11 , 16 , 18 , compare GARDASIL 16- 26-year-old men</brief_summary>
	<brief_title>A Study Compare Immune Response V503 Gardasil 16- 26-year-old Men</brief_title>
	<detailed_description>Secondary objective - To evaluate tolerability 9vHPVvaccine 16- 26-year-old men . - To summarise humoral immune response , include anti-HPV 6 , 11 , 16 , 18 , 31 , 33 , 45 , 52 , 58 GMTs seroconversion rate 4 week post-dose 3 , 16- 26-year-old men receive 9vHPVvaccine GARDASIL</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Subject man , age 16 year 0 day 26 year 364 day day enrolment . Subject man 5 lifetime female sexual partner . Subject judge good physical health basis medical history , physical examination , laboratory result . Subject , subject 's parent guardian , fully understand study procedure , alternative treatment available , risk involve study , voluntarily agree participate give write informed consent . Subject sex male partner . Subject history HPVrelated external genital lesion HPVrelated anal lesion Subject know allergy vaccine component , include aluminium , yeast , BENZONASE Subject history severe allergic reaction require medical intervention . Subject thrombocytopenia coagulation disorder would contraindicate intramuscular injection . Subject concurrently enrol clinical study investigational medicinal product . Subject donate blood within 1 week prior Day 1 vaccination , intend donate Day 1 Month 7 study . Subject currently immunocompromised diagnose congenital acquire immunodeficiency , HIV infection , lymphoma , leukemia , systemic lupus erythematosus , rheumatoid arthritis , juvenile rheumatoid arthritis , inflammatory bowel disease , autoimmune condition . Subject splenectomy . Subject receive received year prior enrolment follow immunosuppressive therapy : radiation therapy , cyclophosphamide , azathioprine , methotrexate , chemotherapy , cyclosporin , leflunomide , TNFÎ± antagonists , monoclonal antibody therapy , intravenous gamma globulin , antilymphocyte serum , therapy know interfere immune response . Subject receive immune globulin product bloodderived product within 6 month prior Day 1 vaccination , plan receive product Day 1 Month 7 study . Subject receive nonreplicating ( inactivate ) vaccine within 14 day prior Day 1 vaccination receive replicating ( live ) vaccine within 21 day prior Day 1 vaccination . Subject receive marketed HPV vaccine , participate HPV vaccine clinical trial receive either active agent placebo . Subject fever within 24hour period prior Day 1 vaccination . Subject history current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study , best interest subject participate . Subject unlikely adhere study procedure , keep appointment , plan relocate study . Subject , time signing informed consent , user recreational illicit drug recent history ( within last year ) drug abuse dependence . Alcohol abuser define drink despite recurrent social , interpersonal , and/or legal problem result alcohol use . Subject , subject 's parent guardian , immediate family member ( spouse child ) investigational site sponsor staff directly involve trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention</keyword>
</DOC>